Join our community of smart investors

AbbVie, J&J and the burgeoning immunology market

Various pharma companies have updated in the last week, shining a light on inflammatory conditions
May 5, 2021
  • Covid-19 has understandably topped the healthcare agenda but there are numerous other disease areas with significant unmet need
  • The immunology market, spanning diseases from psoriasis to arthritis, could be worth $80bn

Vaccines, testing and treatment. Three words that have dominated public discourse over the past 15 months as scientists and governments work hand in glove to tackle Covid-19.

Signalling continued success on its inoculation strategy, Westminster revealed last weekend that more than 50m jabs have now been administered across the UK. More than 34m people have received at least one protective shot. At the same time, the government has made rapid virus tests widely available.

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in